TERIPARATIDE

Post-LOEPeptide

teriparatide

R-Pharm US

ANDASUBCUTANEOUSSOLUTION

Approved

Dec 2025

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

TERIPARATIDE (teriparatide) by R-Pharm US. Approved for parathyroid hormone analog [epc]. First approved in 2025.

Drug data last refreshed 21h ago

$0.1BPart D

Mechanism of Action

Pharmacologic Class:

Parathyroid Hormone Analog

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (20)

NCT07081997Phase 3Recruiting

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

Started Apr 2026

36 enrolled

HypoparathyroidismEndocrine System DiseasesParathyroid Diseases

NCT07264634N/ARecruiting

A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)

Started Mar 2026

10 enrolled

Hypoparathyroidism

NCT07345494N/ARecruiting

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

Started Feb 2026

50 enrolled

Hypoparathyroidism

NCT04589819Phase 4Enrolling By Invitation

Fracture Recovery for Returning to Duty (Teriparatide STRONG)

Started Dec 2022

183 enrolled

Stress Fracture of Tibia or Fibula

NCT05369013N/AUnknown

Study and Follow-up of the Clinical Effectiveness and Comparative Safety of Biosimilar Teriparatide in the Management of Postmenopausal or Senile.

Started Jun 2021

188 enrolled

Osteoporosis

Worked on TERIPARATIDE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.